WO2000059484A3 - Verwendung von arylalkanoylpyridazinen - Google Patents

Verwendung von arylalkanoylpyridazinen Download PDF

Info

Publication number
WO2000059484A3
WO2000059484A3 PCT/EP2000/002280 EP0002280W WO0059484A3 WO 2000059484 A3 WO2000059484 A3 WO 2000059484A3 EP 0002280 W EP0002280 W EP 0002280W WO 0059484 A3 WO0059484 A3 WO 0059484A3
Authority
WO
WIPO (PCT)
Prior art keywords
arylalkanoylpyridazines
tumours
arteriosclerosis
aids
medicament
Prior art date
Application number
PCT/EP2000/002280
Other languages
English (en)
French (fr)
Other versions
WO2000059484A2 (de
Inventor
Jonas Rochus
Michael Wolf
Norbert Beier
Franz-Werner Kluxen
Claus Fittschen
Original Assignee
Merck Patent Gmbh
Jonas Rochus
Michael Wolf
Norbert Beier
Franz-Werner Kluxen
Claus Fittschen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL00350963A priority Critical patent/PL350963A1/xx
Priority to KR1020017011993A priority patent/KR20020000550A/ko
Priority to EP00916949A priority patent/EP1143944A3/de
Priority to MXPA01010034A priority patent/MXPA01010034A/es
Priority to CA002367051A priority patent/CA2367051A1/en
Priority to SK1365-2001A priority patent/SK13652001A3/sk
Application filed by Merck Patent Gmbh, Jonas Rochus, Michael Wolf, Norbert Beier, Franz-Werner Kluxen, Claus Fittschen filed Critical Merck Patent Gmbh
Priority to JP2000609048A priority patent/JP2002541095A/ja
Priority to AU38116/00A priority patent/AU3811600A/en
Priority to BR0009549-4A priority patent/BR0009549A/pt
Publication of WO2000059484A2 publication Critical patent/WO2000059484A2/de
Publication of WO2000059484A3 publication Critical patent/WO2000059484A3/de
Priority to NO20014845A priority patent/NO20014845L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Verwendung von Verbindungen der Formel (I), worin R1, R2, Q und B die in Anspruch 1 angegebenen Bedeutungen haben, und/oder ihrer physiologisch unbedenklichen Salze zur Herstellung eines Arzneimittels zur Behandlung von Osteoporose, Tumoren, Atherosklerose, rheumatoide Arthritis, multiple Sklerose, Diabetes mellitus, ulzerative Kolitis und AIDS.
PCT/EP2000/002280 1999-04-06 2000-03-15 Verwendung von arylalkanoylpyridazinen WO2000059484A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020017011993A KR20020000550A (ko) 1999-04-06 2000-03-15 아릴알카노일피리다진의 용도
EP00916949A EP1143944A3 (de) 1999-04-06 2000-03-15 Verwendung von arylalkanoylpyridazinen
MXPA01010034A MXPA01010034A (es) 1999-04-06 2000-03-15 Uso de arilalcanoilpiridazinas.
CA002367051A CA2367051A1 (en) 1999-04-06 2000-03-15 Use of arylalkanoylpyridazines
SK1365-2001A SK13652001A3 (sk) 1999-04-06 2000-03-15 Použitie derivátov arylalkanoylpyridazínu
PL00350963A PL350963A1 (en) 1999-04-06 2000-03-15 Use of arylalkanoylpyridazines
JP2000609048A JP2002541095A (ja) 1999-04-06 2000-03-15 アリールアルカノイルピリダジンの使用
AU38116/00A AU3811600A (en) 1999-04-06 2000-03-15 Use of arylalkanoylpyridazines
BR0009549-4A BR0009549A (pt) 1999-04-06 2000-03-15 Uso das arilalcanoil piridazinas
NO20014845A NO20014845L (no) 1999-04-06 2001-10-05 Anvendelse av arylalkanoylpyridaziner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915364.7 1999-04-06
DE19915364A DE19915364A1 (de) 1999-04-06 1999-04-06 Verwendung von Arylalkanoylpyridazinen

Publications (2)

Publication Number Publication Date
WO2000059484A2 WO2000059484A2 (de) 2000-10-12
WO2000059484A3 true WO2000059484A3 (de) 2001-08-23

Family

ID=7903583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/002280 WO2000059484A2 (de) 1999-04-06 2000-03-15 Verwendung von arylalkanoylpyridazinen

Country Status (18)

Country Link
EP (1) EP1143944A3 (de)
JP (1) JP2002541095A (de)
KR (1) KR20020000550A (de)
CN (1) CN1355702A (de)
AR (1) AR023261A1 (de)
AU (1) AU3811600A (de)
BR (1) BR0009549A (de)
CA (1) CA2367051A1 (de)
CZ (1) CZ20013598A3 (de)
DE (1) DE19915364A1 (de)
HU (1) HUP0200311A3 (de)
ID (1) ID30381A (de)
MX (1) MXPA01010034A (de)
NO (1) NO20014845L (de)
PL (1) PL350963A1 (de)
RU (1) RU2001129703A (de)
WO (1) WO2000059484A2 (de)
ZA (1) ZA200109120B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040087335A (ko) 2002-03-01 2004-10-13 야마노우치세이야쿠 가부시키가이샤 질소 함유 복소환 화합물
DE10224888A1 (de) * 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
DE10225574A1 (de) * 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
WO2005002590A1 (ja) * 2003-07-01 2005-01-13 Astellas Pharma Inc. 骨量増加誘導剤
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006704A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
WO1999065880A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
WO2000026201A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
WO2000059890A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-derivate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006704A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
WO1999065880A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
WO2000026201A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
WO2000059890A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-derivate

Also Published As

Publication number Publication date
NO20014845D0 (no) 2001-10-05
DE19915364A1 (de) 2000-10-12
CA2367051A1 (en) 2000-10-12
ID30381A (id) 2001-11-29
HUP0200311A2 (hu) 2002-11-28
WO2000059484A2 (de) 2000-10-12
CN1355702A (zh) 2002-06-26
ZA200109120B (en) 2003-11-13
EP1143944A2 (de) 2001-10-17
MXPA01010034A (es) 2002-04-24
JP2002541095A (ja) 2002-12-03
RU2001129703A (ru) 2004-02-20
HUP0200311A3 (en) 2002-12-28
AU3811600A (en) 2000-10-23
AR023261A1 (es) 2002-09-04
CZ20013598A3 (cs) 2002-01-16
BR0009549A (pt) 2002-03-26
EP1143944A3 (de) 2002-09-11
NO20014845L (no) 2001-10-05
PL350963A1 (en) 2003-02-24
KR20020000550A (ko) 2002-01-05

Similar Documents

Publication Publication Date Title
AU6064394A (en) Adhesion receptor antagonists
MY146279A (en) Compounds affecting glucokinase
HK1010722A1 (en) Benzoyl guanidines, their production and their use in medicaments
WO1999064409A3 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
GEP20053488B (en) Novel Spiro Compounds
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
GB0013737D0 (en) Novel compounds
WO2002036135A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
IT1307267B1 (it) Procedimento di rafforzamento di attivita' antitumorale di farmacigrezzi, composizione contenente un farmaco grezzo rafforzante
NZ515025A (en) Solvates of pymetrozine
WO2000059484A3 (de) Verwendung von arylalkanoylpyridazinen
ZA946196B (en) New bis-naphthalimides for the treatment of cancer
MXPA04002639A (es) Uso de inhibidores de fosfodiesterasa iv.
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
WO2001016096A3 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
WO2003024941A1 (fr) Composes de naphtalene et leur utilisation comme medicament
WO2000051579A3 (de) Verwendung von polycyclischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
WO2001017959A3 (en) Vitronectin receptor antagonists
CZ91995A3 (en) Gestagen-active 19,11-bridged 4-esterenes, process of their preparation and intermediate for preparing thereof
EP0487996B1 (de) 3-substituierte Cephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2000007544A3 (en) Vitronectin receptor antagonists
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
WO2002051845A3 (en) Triazolopyrimidines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805648.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000916949

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017011993

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 13652001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2367051

Country of ref document: CA

Ref document number: 2367051

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010034

Country of ref document: MX

Ref document number: 09958121

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV2001-3598

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 609048

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000916949

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1142/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001/09120

Country of ref document: ZA

Ref document number: 38116/00

Country of ref document: AU

Ref document number: 200109120

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1200101073

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020017011993

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-3598

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916949

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-3598

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011993

Country of ref document: KR